Case Report
Copyright ©The Author(s) 2022.
World J Clin Cases. Mar 16, 2022; 10(8): 2550-2558
Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2550
Table 1 Antimicrobial-susceptibility of the isolated strain on May 30th and June 7th
Antibiotics
MIC (mg/mL)
MIC categories
Pre-test
Post-test
Pre-test
Post-test
Penicillin G≥ 0.5≥ 0.5RR
Oxacillin≥ 4≥ 4RR
Gentamicin≤ 0.5≤ 0.5SS
Levofloxacin0.50.5SS
Erythromycin≥ 8≥ 8RR
Clindamycin≥ 4≥ 4RR
Linezolid22SS
Teicoplanin≤ 0.5≤ 0.5SS
Vancomycin≤ 0.51SS
Tigecycline≤ 0.12≤ 0.12SS
Table 2 Clinical factors, treatment details, and outcomes among 3 patients treated with Daptomycin and linezolid for methicillin-resistant Staphylococcus aureus bacteremia and complication.
Patients
Ref.
Reason for Daptomycin/linezolid use
Host factors
Complication
Prior antimicrobialtherapy
Other active antimicrobials available
Daptomycin/linezolid dose; duration
MIC (mg/mL)
Outcome, follow-up duration
1Kelesidis et al[21], 2011Allergy62 y/o with placement of the coatrial andlumboperitoneal shuntsMeningitisDaptomycinVancomycinDaptomycin (NS); linezolid (600 mg twice daily); 4 dDaptomycin (≤ 0.5 μg /mL), vancomycin (1 μg /mL), linezolid (4 μg/mL), rifampin (0.06 μg/mL)Clinical cure, NS
2Yazaki et al[22], 2018Allergy, acute kidney injury26 y/o woman with surgical closure of ventricular septal defectSeptic pulmonary embolismLevofloxacin, meropenem, azithromycin, vancomycin, rifampicin, gentamicinNoneDaptomycin (8 mg/kg q48h), linezolid (600 mg q12h); 6 wkVancomycin (1 μg/mL), Linezolid (2 μg/mL), Daptomycin (1 μg/mL)Clinical cure, 2 mo
3Galanter et al[23], 2019Vancomycin resistance, worsening of septic emboli in both lungs, blood cultures remained positive for MRSA 26 y/o woman with native tricuspid value endocarditisSuspected septic embolismVancomycin, daptomycin, gentamicinNoneDaptomycin (8 mg/kg iv daily), linezolid (600 mg iv twice daily), 15 dDaptomycin 1 μg/mL; daptomycin MIC 4 μg/mL (on the 15th day)Clinical cure, 6 wk